OA10.04 Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study.
| Autor: | Lau, S., Ahn, M.-J., Moskovitz, M., Pogorzelski, M., Haefliger, S., Paulson, K.G., Parkes, A., Zhang, Y., Hamidi, A., Wermke, M. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2024 Supplement, Vol. 19 Issue 10, pS31-S32, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|